SCHEMBL29408692

SCHEMBL29408692

CCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O

nearest known ligand 0.74

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CCKBR P32239 15/20 0.74
CCKAR P32238 5/20 0.73
OPRD1 P41143 1/20 0.73
NPY1R P25929 3/20 0.64
NPY2R P49146 3/20 0.64
NPY4R P50391 3/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30037697 0.96 CCKBR (0.77) CCKBRCCKAROPRD1
SCHEMBL29367056 0.95 CCKBR (0.73) CCKBRCCKAROPRD1NPY1RNPY2R
SCHEMBL29370482 0.95 CCKBR (0.76) CCKBRCCKAROPRD1
SCHEMBL30887334 0.94 CCKBR (0.71) CCKBRCCKAROPRD1NPY1RNPY2R
SCHEMBL30951444 0.93 CCKBR (0.82) CCKBRCCKAROPRD1
SCHEMBL31015845 0.93 CCKBR (0.82) CCKBRCCKAROPRD1
SCHEMBL30887325 0.93 CCKBR (0.70) CCKBRCCKAROPRD1NPY1RNPY2R
SCHEMBL30533211 0.92 CCKBR (0.83) CCKBRCCKAROPRD1
SCHEMBL29408674 0.92 CCKBR (0.72) CCKBRCCKAROPRD1
SCHEMBL29414561 0.92 CCKBR (0.80) CCKBRCCKAROPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605447-B2 Stable formulations for radionuclide complexes ITM SOLUCIN GMBH (DE) 2026-04-21 US disclosed
US-20250170243-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2025-05-29 US disclosed
US-20240374732-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2024-11-14 US disclosed
US-20230414796-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM Isotope Technologies Munich SE (DE) 2023-12-28 US disclosed
EP-4065176-B1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER ITM ISOTOPE TECH MUNICH SE (DE) 2023-10-11 EP disclosed
EP-4218749-A1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE ITM Isotope Technologies Munich SE (DE) 2023-08-02 EP disclosed
EP-3965751-B1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE ITM ISOTOPE TECH MUNICH SE (DE) 2022-12-28 EP disclosed
US-20220304964-A1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2022-09-29 US disclosed
CN-114126654-A Para-aminohippuric acid (PAH) as a kidney protective substance 同位素技术慕尼黑有限公司 2022-03-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605447-B2 Stable formulations for radionuclide complexes EPOR, CD47, PRCP CCKBR 107/4885CCKAR 88/4885OPRD1 797/4885
US-20250170243-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES SLC40A1, SLC7A11, GYPA CCKBR 1119/4885CCKAR 1147/4885OPRD1 3845/4885
US-20220304964-A1 PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE PAH, SLCO1B1, SLCO2B1 CCKBR 1100/4885CCKAR 855/4885OPRD1 3805/4885
US-20240374732-A1 STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES SLC40A1, SLC7A11, GYPA CCKBR 1085/4885CCKAR 1163/4885OPRD1 3821/4885
US-20230414796-A1 COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER PAH, VHL, SLC10A6 CCKBR 389/4885CCKAR 404/4885OPRD1 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.